Shopping Cart 0
Cart Subtotal
USD 0

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Retinitis Pigmentosa (Retinitis)-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis)-Pipeline Review, H1 2018, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis)-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 12, 3, 31 and 7 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 11 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Retinitis Pigmentosa (Retinitis)-Overview 6

Retinitis Pigmentosa (Retinitis)-Therapeutics Development 7

Retinitis Pigmentosa (Retinitis)-Therapeutics Assessment 18

Retinitis Pigmentosa (Retinitis)-Companies Involved in Therapeutics Development 26

Retinitis Pigmentosa (Retinitis)-Drug Profiles 40

Retinitis Pigmentosa (Retinitis)-Dormant Projects 162

Retinitis Pigmentosa (Retinitis)-Discontinued Products 164

Retinitis Pigmentosa (Retinitis)-Product Development Milestones 165

Appendix 180


List Of Figure

List of Figures

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Acucela Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Allergan Plc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Amgen Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Applied Genetic Technologies Corp, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Astellas Pharma Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Dompe Farmaceutici SpA, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by EyePoint Pharmaceuticals Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Eyevensys SAS, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by GenSight Biologics SA, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Grupo Ferrer Internacional SA, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Horama SA, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by ID Pharma Co Ltd, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by InFlectis BioScience, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by M's Science Corp, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by MimeTech Srl, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Miragen Therapeutics Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Nanovector srl, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Novartis AG, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Novelion Therapeutics Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Profarma, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by ProQR Therapeutics NV, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Recursion Pharmaceuticals Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by ReNeuron Group Plc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by SanBio Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Sanofi, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Spark Therapeutics Inc, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Retinitis Pigmentosa (Retinitis)-Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Retinitis Pigmentosa (Retinitis)-Dormant Projects, H1 2018

Retinitis Pigmentosa (Retinitis)-Dormant Projects, H1 2018 (Contd..1), H1 2018

Retinitis Pigmentosa (Retinitis)-Discontinued Products, H1 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Retinitis Pigmentosa (Retinitis) Therapeutic Products under Development, Key Players in Retinitis Pigmentosa (Retinitis) Therapeutics, Retinitis Pigmentosa (Retinitis) Pipeline Overview, Retinitis Pigmentosa (Retinitis) Pipeline, Retinitis Pigmentosa (Retinitis) Pipeline Assessment


Companies

Acucela Inc

Allergan Plc

Amarantus Bioscience Holdings Inc

Amgen Inc

Applied Genetic Technologies Corp

Astellas Pharma Inc

Dompe Farmaceutici SpA

EyePoint Pharmaceuticals Inc

Eyevensys SAS

GenSight Biologics SA

Grupo Ferrer Internacional SA

Horama SA

ID Pharma Co Ltd

InFlectis BioScience

Ionis Pharmaceuticals Inc

M's Science Corp

MimeTech Srl

Miragen Therapeutics Inc

Nanovector srl

Novartis AG

Novelion Therapeutics Inc

Profarma

ProQR Therapeutics NV

Recursion Pharmaceuticals Inc

ReNeuron Group Plc

SanBio Inc

Sanofi

Spark Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd